The initial response to levodopa in Parkinson's disease (PD) is generally one of marked, sustained improvement in motor function. With long-term levodopa treatment, this response is replaced by fluctuating response which may be very disabling and is resistant to therapeutic manipulations. We hypothesize that the motor function in levodopa-treated PD is a product of the short-duration response (SDR) to levodopa, with a half-life of hours; the long-duration response (LDR) to levodopa, with a half-life of days; and endogenous dopamine production. The initial, good response to levodopa is dominated by the LDR. The development of fluctuations reflects reduction of the LDR and endogenous dopamine synthesis caused by disease progression and, possible, levodopa treatment. Further, we hypothesize that the diurnal motor variation noted as morning improvement and evening deterioration in motor function in PD may be a marker of impaired endogenous dopamine synthesis. This proposal switches the emphasis from the SDR which has dominated the thinking about the motor response to levodopa to the LDR which has been largely ignored.
The aims of this clinical study are: 1.) Examine the changes in the SDR and LDR during the first 4 years of levodopa treatment and correlate them with the emergence of clinically apparent motor fluctuations to determine the relative contribution of the SDR and LDR to fluctuations. 2.) Examine the SDR and LDR in dopa-responsive dystonia (DRD), a form of parkinsonism in which dopamine synthesis is impaired but dopamine storage is intact, to determine the importance of dopamine storage to the SDR and LDR. 3.) Determine if apomorphine, a dopamine agonist, will sustain the LDR to establish if the LDR is a pre- or a postsynaptic action. 4.) Examine the diurnal motor variation in PD, DRD and normal controls to determine if diurnal motor variation is a marker for impaired dopamine neurotransmission. Also determine is motor activity influences the diurnal pattern in PD to suggest that depletion of dopamine could underlie the phenomenon. Our overall goal is to understand the fluctuating response to levodopa. The major thrust for this grant period is to determine the contribution of the LDR to the benefits of levodopa treatment and to suggest methods to selectively induce or augment the LDR.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Neurology A Study Section (NEUA)
Program Officer
Oliver, Eugene J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Holford, Nick H G; Nutt, John G (2011) Interpreting the results of Parkinson's disease clinical trials: time for a change. Mov Disord 26:569-77
Zampieri, Cris; Salarian, Arash; Carlson-Kuhta, Patricia et al. (2011) Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test. Parkinsonism Relat Disord 17:277-80
Kay, D M; Stevens, C F; Hamza, T H et al. (2010) A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 75:1189-94
Chung, Kathryn A; Lobb, Brenna M; Nutt, John G et al. (2010) Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord 25:602-8
Brodsky, Matthew A; Park, Byung S; Nutt, John G (2010) Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch Neurol 67:27-32
Nutt, John G; Chung, Kathy A; Holford, Nicholas H G (2010) Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 74:1191-7
Chung, Kathryn A; Lobb, Brenna M; Nutt, John G et al. (2010) Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75:1263-9
Gunzler, Steven A; Pavel, Misha; Koudelka, Caroline et al. (2009) Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials. Clin Neuropharmacol 32:97-102
Peterson, Amie L; Nutt, John G (2008) Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5:270-80
Holford, Nick; Nutt, John G (2008) Disease progression, drug action and Parkinson's disease: why time cannot be ignored. Eur J Clin Pharmacol 64:207-16

Showing the most recent 10 out of 68 publications